Intrinsic Medicine, Inc. (INRX)

Intrinsic Medicine will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.00 - $7.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
Market Cap67.74M
Revenue (ttm)n/a
Net Income (ttm)-11.95M
Shares Out11.29M
EPS (ttm)-1.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About INRX

Intrinsic Medicine is a preclinical-stage therapeutics company leveraging synthetic biology-manufactured human identical milk oligosaccharide, or HiMO, molecules as new medicines to treat large patient populations underserved by current treatment options. In the first half of 2023, we plan to initiate a Phase 2 clinical trial under an approved protocol in Australia to test our lead drug candidate in over 400 patients with the constipation dominant form of irritable bowel syndrome, or IBS-C, which is estimated to affect approximately five millio...

IndustryHealth Care
Founded2018
CEOAlexander Martinez
Employees8
Stock ExchangeNASDAQ
Ticker SymbolINRX
Full Company Profile

Financial Performance

Financial Statements

News

Inflammatory disease biotech Intrinsic Medicine files for a $29 million IPO

Intrinsic Medicine, a preclinical biotech developing HiMO therapies for GBA and inflammatory disorders, filed on Friday with the SEC to raise up to $29 million in an initial public offering.

1 month ago - Renaissance Capital

Intrinsic Medicine IPO Registration Document (S-1)

Intrinsic Medicine has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC